A Phase 1 interventional study of 1 mg islatravir and 2 mg islatravir in HIV-1, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-08-12.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the safety, tolerability, pharmacokinetics, and anti-retroviral therapy (ART) activity of islatravir (MK-8591) monotherapy in ART-naive, human immunodeficiency virus-1 (HIV-1) infected participants. The primary hypothesis is that at a safe and tolerable dose of islatravir, the true mean difference in the plasma HIV-1 ribonucleic acid (RNA) reduction from baseline between islatravir and placebo is at least 0.5 log (base10) copies/mL.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single oral dose of islatravir 1 mg
Drug: 1 mg islatravir
Single oral dose of islatravir 2 mg
Drug: 2 mg islatravir
Single oral dose of islatravir 10 mg
Drug: 10 mg islatravir
Single oral dose of islatravir 30 mg
Drug: 30 mg islatravir
Single oral dose of islatravir 0.5 mg
Drug: 0.5 mg islatravir
Single oral dose of islatravir 0.25 mg
Drug: 0.25 mg islatravir
Single oral dose of 30 mg islatravir administered following \>8 hour fast. Participants will be closely monitored for viral load for up to approximately 21 days prior to starting standard of care ART.
Drug: 30 mg islatravir
Single oral dose of 1 mg islatravir administered following ≥8 hour fast
Also known as: MK-8591
Single oral dose of 2 mg islatravir administered following ≥8 hour fast
Also known as: MK-8591
Single oral dose of 10 mg islatravir administered following ≥8 hour fast
Also known as: MK-8591
Single oral dose of 30 mg islatravir administered following ≥8 hour fast
Also known as: MK-8591
Single oral dose of 0.5 mg islatravir administered following ≥8 hour fast
Also known as: MK-8591
Single oral dose of 0.25 mg islatravir administered following ≥8 hour fast
Also known as: MK-8591
Change From Baseline in Plasma HIV-1 RNA at 168 Hours Post-Dose
Plasma HIV-1 RNA was measured using the Roche COBAS Ampliprep/COBAS TaqMan HIV-1 test v.2.0, which has a linear range from 20 to 10,000,000 copies/mL. The lower limit of detection has 100% specificity at 20 copies/mL. Additionally, the test increases the probability of detection and expands coverage by targeting two highly conserved regions of the HIV-1 genome to compensate for the possibility of mutations or mismatches.
Time frame: Baseline and 168 hours (7 days) post-dose
Number of Participants With One or More Adverse Events
An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
Time frame: Up to 21 days post-dose
Area Under the Concentration-Time Curve of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells From Time 0 to 168 Hours (AUC0-168hr)
Blood was collected to measure intracellular islatravir triphosphate concentration in peripheral blood mononuclear cells and determine AUC0-168hr.
Time frame: 4, 12, 24, 96, 120, 144, and 168 hours after islatravir administration. Value at predose was inferred from plasma predose sample.
Maximum Concentration (Cmax) of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells
Blood was collected to measure intracellular islatravir triphosphate concentration in peripheral blood mononuclear cells and determine Cmax.
Time frame: 4, 12, 24, 96, 120, 144, and 168 hours after islatravir administration. Value at predose was inferred from plasma predose sample.
Concentration of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells at 168 Hours Post-Dose (C168hr)
Blood was collected to measure intracellular islatravir triphosphate concentration in peripheral blood mononuclear cells and determine C168hr.
Time frame: 168 hours after islatravir administration
Time to Maximum Concentration (Tmax) of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells
Blood was collected to measure intracellular islatravir triphosphate concentration in peripheral blood mononuclear cells and determine TMax.
Time frame: 4, 12, 24, 96, 120, 144, and 168 hours after islatravir administration. Value at predose was inferred from plasma predose sample.
Apparent Terminal Half-Life (t1/2) of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells
Blood was collected to measure intracellular islatravir triphosphate concentration in peripheral blood mononuclear cells and determine apparent terminal t1/2.
Time frame: 4, 12, 24, 96, 120, 144, and 168 hours after islatravir administration. Value at predose was inferred from plasma predose sample.
Area Under the Plasma Concentration-Time Curve of Islatravir From Time 0 to 168 Hours (AUC0-168hr)
Blood was collected for the determination of AUC0-168hr of islatravir in plasma.
Time frame: Predose and at 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, and 96 hours after islatravir administration. Value at 168 hours was extrapolated.
Maximum Plasma Concentration (Cmax) of Islatravir
Blood was collected for the determination of Cmax of islatravir in plasma.
Time frame: Predose and at 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, and 96 hours after islatravir administration
Time to Maximum Plasma Concentration (Tmax) of Islatravir
Blood was collected for the determination of Tmax of islatravir in plasma.
Time frame: Predose and at 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, and 96 hours after islatravir administration
Apparent Terminal Half-Life (t1/2) of Islatravir in Plasma
Blood was collected for the determination of apparent terminal t1/2 of islatravir in plasma.
Time frame: Predose and at 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, and 96 hours after islatravir administration
| Milestone | Panel A: 10 mg Islatravir | Panel B: 2 mg Islatravir | Panel C: 30 mg Islatravir | Panel D: 1 mg Islatravir | Panel E: 0.5 mg Islatravir | Panel F: 0.25 mg Islatravir | Panel G: 30 mg Islatravir Extended Observation |
|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 0 | 0 |
| Completed | 6 | 6 | 6 | 6 | 6 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Plasma HIV-1 RNA was measured using the Roche COBAS Ampliprep/COBAS TaqMan HIV-1 test v.2.0, which has a linear range from 20 to 10,000,000 copies/mL. The lower limit of detection has 100% specificity at 20 copies/mL. Additionally, the test increases the probability of detection and expands coverage by targeting two highly conserved regions of the HIV-1 genome to compensate for the possibility of mutations or mismatches.
| log10 copies/mL | Panel A: 10 mg Islatravir | Panel B: 2 mg Islatravir | Panel C: 30 mg Islatravir | Panel D: 1 mg Islatravir | Panel E: 0.5 mg Islatravir |
|---|---|---|---|---|---|
| Change From Baseline in Plasma HIV-1 RNA at 168 Hours Post-Dose | -1.67 (-1.92 to -1.42) | -1.35 (-1.60 to -1.10) | -1.60 (-1.85 to -1.34) | -1.30 (-1.55 to -1.05) | -1.20 (-1.46 to -0.95) |
An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
| Participants | Panel A: 10 mg Islatravir | Panel B: 2 mg Islatravir | Panel C: 30 mg Islatravir | Panel D: 1 mg Islatravir | Panel E: 0.5 mg Islatravir |
|---|---|---|---|---|---|
| Number of Participants With One or More Adverse Events | 5 | 5 | 6 | 5 | 6 |
Blood was collected to measure intracellular islatravir triphosphate concentration in peripheral blood mononuclear cells and determine AUC0-168hr.
| hr*pmol/10^6 cells | Panel A: 10 mg Islatravir | Panel B: 2 mg Islatravir | Panel C: 30 mg Islatravir | Panel D: 1 mg Islatravir | Panel E: 0.5 mg Islatravir |
|---|---|---|---|---|---|
| Area Under the Concentration-Time Curve of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells From Time 0 to 168 Hours (AUC0-168hr) | 227 ± 33.3 | 46.9 ± 38.1 | 926 ± 47.7 | 35.9 ± 27.6 | 23.1 ± 83.0 |
Blood was collected to measure intracellular islatravir triphosphate concentration in peripheral blood mononuclear cells and determine Cmax.
| pmol/10^6 cells | Panel A: 10 mg Islatravir | Panel B: 2 mg Islatravir | Panel C: 30 mg Islatravir | Panel D: 1 mg Islatravir | Panel E: 0.5 mg Islatravir |
|---|---|---|---|---|---|
| Maximum Concentration (Cmax) of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells | 2.81 ± 49.9 | 0.495 ± 62.9 | 8.9 ± 60.3 | 0.408 ± 49.3 | 0.263 ± 54.5 |
Blood was collected to measure intracellular islatravir triphosphate concentration in peripheral blood mononuclear cells and determine C168hr.
| pmol/10^6 cells | Panel A: 10 mg Islatravir | Panel B: 2 mg Islatravir | Panel C: 30 mg Islatravir | Panel D: 1 mg Islatravir | Panel E: 0.5 mg Islatravir |
|---|---|---|---|---|---|
| Concentration of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells at 168 Hours Post-Dose (C168hr) | 0.983 ± 26 | 0.188 ± 39.2 | 4.83 ± 85.9 | 0.164 ± 31.4 | 0.116 ± 85.6 |
Blood was collected to measure intracellular islatravir triphosphate concentration in peripheral blood mononuclear cells and determine TMax.
| Hour | Panel A: 10 mg Islatravir | Panel B: 2 mg Islatravir | Panel C: 30 mg Islatravir | Panel D: 1 mg Islatravir | Panel E: 0.5 mg Islatravir |
|---|---|---|---|---|---|
| Time to Maximum Concentration (Tmax) of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells | 12 (12 to 240) | 8 (4 to 144) | 24 (4 to 96) | 8 (4 to 24) | 12 (4 to 24) |
Blood was collected to measure intracellular islatravir triphosphate concentration in peripheral blood mononuclear cells and determine apparent terminal t1/2.
| Hours | Panel A: 10 mg Islatravir | Panel B: 2 mg Islatravir | Panel C: 30 mg Islatravir | Panel D: 1 mg Islatravir | Panel E: 0.5 mg Islatravir |
|---|---|---|---|---|---|
| Apparent Terminal Half-Life (t1/2) of Islatravir Triphosphate in Peripheral Blood Mononuclear Cells | 128 ± 42.2 | 120 ± 14.7 | 78.5 ± 31.4 | 118 ± 16.1 | 95.3 ± 38.2 |
Blood was collected for the determination of AUC0-168hr of islatravir in plasma.
| hr*nM | Panel A: 10 mg Islatravir | Panel B: 2 mg Islatravir | Panel C: 30 mg Islatravir | Panel D: 1 mg Islatravir | Panel E: 0.5 mg Islatravir |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve of Islatravir From Time 0 to 168 Hours (AUC0-168hr) | 1020 ± 16.8 | 143 ± 39.6 | 3020 ± 24.6 | 88.3 ± 33.8 | 38.3 ± 25.8 |
Blood was collected for the determination of Cmax of islatravir in plasma.
| nM | Panel A: 10 mg Islatravir | Panel B: 2 mg Islatravir | Panel C: 30 mg Islatravir | Panel D: 1 mg Islatravir | Panel E: 0.5 mg Islatravir |
|---|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Islatravir | 235 ± 32.1 | 43.8 ± 51.2 | 678 ± 29.6 | 38.8 ± 31.3 | 20.3 ± 36.4 |
Blood was collected for the determination of Tmax of islatravir in plasma.
| Hour | Panel A: 10 mg Islatravir | Panel B: 2 mg Islatravir | Panel C: 30 mg Islatravir | Panel D: 1 mg Islatravir | Panel E: 0.5 mg Islatravir |
|---|---|---|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) of Islatravir | 1 (0.5 to 1) | 0.5 (0.5 to 1) | 0.75 (0.5 to 1) | 0.5 (0.5 to 1) | 0.5 (0.25 to 0.5) |
Blood was collected for the determination of apparent terminal t1/2 of islatravir in plasma.
| Hours | Panel A: 10 mg Islatravir | Panel B: 2 mg Islatravir | Panel C: 30 mg Islatravir | Panel D: 1 mg Islatravir | Panel E: 0.5 mg Islatravir |
|---|---|---|---|---|---|
| Apparent Terminal Half-Life (t1/2) of Islatravir in Plasma | 59.7 ± 15.4 | 47.4 ± 74.6 | 56.8 ± 11.2 | 10.4 ± 144 | 2.31 ± 16.7 |
Collected over Up to 21 days following administration of investigational drug. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panel A: 10 mg Islatravir | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Panel B: 2 mg Islatravir | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Panel C: 30 mg Islatravir | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Panel D: 1 mg Islatravir | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Panel E: 0.5 mg Islatravir | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Event | Panel A: 10 mg Islatravir | Panel B: 2 mg Islatravir | Panel C: 30 mg Islatravir | Panel D: 1 mg Islatravir | Panel E: 0.5 mg Islatravir |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 5/6 | 1/6 | 0/6 | 2/6 | 2/6 |
| Viral upper respiratory tract infectionInfections and infestations | 0/6 | 0/6 | 3/6 | 1/6 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 1/6 | 2/6 | 1/6 | 1/6 | 1/6 |
| VomitingGastrointestinal disorders | 0/6 | 0/6 | 1/6 | 2/6 | 0/6 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/6 | 1/6 | 0/6 | 2/6 | 0/6 |
| Angina pectorisCardiac disorders | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 |
| Abdominal painGastrointestinal disorders | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 |
| Abdominal pain upperGastrointestinal disorders | 1/6 | 0/6 | 0/6 | 0/6 | 1/6 |
| NauseaGastrointestinal disorders | 1/6 | 0/6 | 0/6 | 1/6 | 0/6 |
| Oral mucosa erosionGastrointestinal disorders | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 |
| Age, Continuous(Years) | Panel A: 10 mg Islatravir | Panel B: 2 mg Islatravir | Panel C: 30 mg Islatravir | Panel D: 1 mg Islatravir | Panel E: 0.5 mg Islatravir | Total |
|---|---|---|---|---|---|---|
| Mean | 31.5 ± 10.0 | 42.2 ± 9.8 | 35.5 ± 9.1 | 32.7 ± 12.7 | 35.5 ± 11.3 | 35.5 ± 10.6 |
| Sex: Female, Male(Participants) | Panel A: 10 mg Islatravir | Panel B: 2 mg Islatravir | Panel C: 30 mg Islatravir | Panel D: 1 mg Islatravir | Panel E: 0.5 mg Islatravir | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 6 | 6 | 6 | 6 | 6 | 30 |
| Ethnicity (NIH/OMB)(Participants) | Panel A: 10 mg Islatravir | Panel B: 2 mg Islatravir | Panel C: 30 mg Islatravir | Panel D: 1 mg Islatravir | Panel E: 0.5 mg Islatravir | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 0 | 1 | 0 | 3 |
| Not Hispanic or Latino | 4 | 6 | 6 | 5 | 6 | 27 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Panel A: 10 mg Islatravir | Panel B: 2 mg Islatravir | Panel C: 30 mg Islatravir | Panel D: 1 mg Islatravir | Panel E: 0.5 mg Islatravir | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 6 | 6 | 6 | 5 | 6 | 29 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Plasma HIV-1 Ribonucleic Acid (RNA)(log10 copies/mL) | Panel A: 10 mg Islatravir | Panel B: 2 mg Islatravir | Panel C: 30 mg Islatravir | Panel D: 1 mg Islatravir | Panel E: 0.5 mg Islatravir | Total |
|---|---|---|---|---|---|---|
| Mean | 4.68 ± 0.39 | 4.7 ± 0.25 | 4.17 ± 0.41 | 4.66 ± 0.2 | 4.59 ± 0.5 | 4.56 ± 0.40 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Sep 2015 to primary completion in May 2017, 19 months.
Results were first posted in Dec 2018, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Islatravir